| 1 |
Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 2 |
Courbette O, Aupiais C, Viala J, Hugot JP, Louveau B, Chatenoud L, Bourrat E, Martinez-Vinson C. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:189-93. [PMID: 30921262 DOI: 10.1097/MPG.0000000000002349] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 3 |
Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018;57:1521-32. [DOI: 10.1111/ijd.14072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 4 |
Kolios AGA, Biedermann L, Weber A, Navarini AA, Meier J, Cozzio A, French LE. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. Br J Dermatol. 2018;178:551-555. [PMID: 28477389 DOI: 10.1111/bjd.15631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 5 |
Lee SH, Kim YS, Kim HJ, Park YL. Psoriasis, Vitiligo and Crohn's Disease Co-Existing in a Single Patient: A Variant Type of Multiple Autoimmune Syndrome? Ann Dermatol 2017;29:782-5. [PMID: 29200770 DOI: 10.5021/ad.2017.29.6.782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 6 |
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 2017;23:1174-81. [PMID: 28452862 DOI: 10.1097/MIB.0000000000001109] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 7 |
Campanati A, Benfaremo D, Luchetti MM, Ganzetti G, Gabrielli A, Offidani A. Certolizumab pegol for the treatment of psoriasis. Expert Opinion on Biological Therapy 2017;17:387-94. [DOI: 10.1080/14712598.2017.1283401] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 8 |
Colìa R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann Med 2016;48:577-85. [PMID: 27310096 DOI: 10.1080/07853890.2016.1195011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 9 |
Vedak P, Kroshinsky D, St John J, Xavier RJ, Yajnik V, Ananthakrishnan AN. Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther 2016;43:697-704. [PMID: 26806281 DOI: 10.1111/apt.13542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci 2015;60:3424-30. [PMID: 26115749 DOI: 10.1007/s10620-015-3763-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 11 |
Brandse JF, Vos LM, Jansen J, Schakel T, Ponsioen CI, van den Brink GR, D'Haens GR, Löwenberg M. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. J Crohns Colitis 2015;9:973-81. [PMID: 26116557 DOI: 10.1093/ecco-jcc/jjv116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 12 |
Certolizumab pegol/infliximab. Reactions Weekly 2015;1564:48-48. [DOI: 10.1007/s40278-015-4191-9] [Reference Citation Analysis]
|
| 13 |
Cabaleiro T, Prieto-Pérez R, Navarro R, Solano G, Román M, Ochoa D, Abad-Santos F, Daudén E. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J 2016;16:336-40. [PMID: 26194362 DOI: 10.1038/tpj.2015.53] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 14 |
Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015;26:25-33. [PMID: 25434285 DOI: 10.1016/j.cytogfr.2014.10.009] [Cited by in Crossref: 114] [Cited by in F6Publishing: 123] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 15 |
Brinkworth JF, Barreiro LB. The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease. Curr Opin Immunol 2014;31:66-78. [PMID: 25458997 DOI: 10.1016/j.coi.2014.09.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 16 |
Sampaio-barros PD, van der Horst-bruinsma IE. Adverse effects of TNF inhibitors in SpA: Are they different from RA? Best Practice & Research Clinical Rheumatology 2014;28:747-63. [DOI: 10.1016/j.berh.2014.10.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
|
